摘要
生物医药产业作为永远的朝阳产业受到世界各国特别是美欧等发达国家的重视。近年来,我国生物医药产业集群呈现出快速发展态势,已初步形成长三角、珠三角和环渤海三大生物医药产业集群板块。但与国外成熟的生物医药产业集群相比,我国生物医药产业集群整体竞争力偏弱,亟待升级与竞争力提升。本文基于生物医药产业价值链视角,梳理了我国生物医药产业集群发展状况,然后根据生物医药产业价值链的构成及特点,提出我国生物医药产业集群升级的可行模式与适用条件。
As an eternal sunrise industry, bio -pharmaceutical industry has been valued in many countries, and has devel- oped rapidly in China, in which it was formed in three bio - pharmaceutical industry clusters as Yangtze River Delta, Pearl River Delta and Bohai Rim. Compared with foreign mature bio - pharmaceutical industry clusters, Chinese clusters have insufficient competitiveness, which needs to be upgraded urgently. The status of development of bio - pharmaceutical industry cluster in China was analyzed in view of industry value chain. Based on its characteristics, the feasible upgrading mode and applicable conditions of Chinese bio - pharmaceutical industry clusters were put forward.
出处
《中国卫生事业管理》
北大核心
2017年第12期884-887,894,共5页
Chinese Health Service Management
基金
江苏省社会科学基金"江苏生物医药产业关键技术预见与创新战略选择研究"(编号:14GLB007)
江苏省高校哲学社会科学基金"江苏生物医药创新集群演化机理与发展策略研究--基于CAS视角"(编号:2016SJB790018)
关键词
生物医药产业
产业集群
价值链
升级模式
bio -pharmaceutical industry
industry cluster
value chain
upgrading mode
